Posted on 03/09/2009 in Pharmaceutical Company Product News Sanofi-aventis has revealed the results of a new trial into the anti-Xa intravenous coagulant otamixaban.
The trial showed that the treatment reduced the likelihood by 27 to 42 per cent of the composite primary endpoint of death, urgent revascularisation, myocardial infarcaton or rescue GPIIb/IIIa use in four out of five otamixaban tested doses versus standard UFH/eptifibatide combinations in non-ST ACS patients.
Otamixaban is a product that emerged from Sanofi-aventis' record of thrombosis research and is a rapid onset, first-in-class antithrombotic compound which acts as a direct selective inhibitor of factor Xa.
Dr Marc Sabatine, a cardiologist at Brigham and Women's Hospital, stated: "This research is addressing an important medical need, by potentially significantly improving outcomes of ACS patients undergoing PCI while simplifying the treatment pattern of the acute management phase of the disease."
In other Sanofi-aventis news, the firm revealed a number of new appointments yesterday as it attempts to restructure to the benefit of the clients it serves.
Other news stories from 03/09/2009
Read more in the Zenopa News Archive
How this news is generated
|
